

FTO

A Gene Contributing to Human Obesity

The *Fto* gene was first cloned after identification of a Fused toe (Ft) mutant mouse, whose phenotype arised from a 1.6mb deletion of six genes, including *Fto* [1, 2]. *FTO* is a very large gene, also known as fat mass and obesity associated gene. In human, it is located on chromosome 16, consisting of 9 exons and spanning more than 400kb [3]. *FTO* mRNA is widely expressed in different tissues, especially in the brain, but also in skeletal muscles and adipose tissue [3, 4, 5, 6]. In the mice brain, *Fto* is highly expressed in hypothalamic nuclei that control eating behavior [7, 8]. It was believed, that only vertebrates are carriers of the *FTO/Fto* gene. To date, also *FTO* homologs in evolutionary diverse marine eukaryotic algae were identified. The biological roles of these *FTO* homologs are still unknown [9].

Four regions in the *FTO* gene are particularly well conserved and three of them are homologous to *E. coli* AlkB and its eukaryotic homologs, members of the ABH (AlkB homolog) family [4]. AlkB is a member of the 2OG-FE(II) oxygenase superfamiliy that oxidatively demethylates DNA [4, 10]. 2OG-FE(II) oxygenases are involved in diverse processes, such as DNA repair, fatty acid metabolism and posttranslational modifications. *In vitro* studies have shown, that FTO can catalyze the demethylation of 3-methyluracil in single-stranded RNA with a slightly higher efficiency over that of 3-methylthymine in double- or single-stranded DNA [11]. Crystal structure analysis of the FTO protein provides a structural basis for the substrate specificity and the ability of FTO to distinguish 3-methyluracil and 3-methyl-

CONTINUED ON NEXT PAGE

NEW!

FTO ELISA Kits

Excellent Quality • High Sensitivity • Batch-to-Batch Reproducibility

FTO (human) (IntraCellular) ELISA Kit

AG-45A-0025EK-KI01

AG-45A-0025TP-KI01 Twin Plex

1 x 96 wells

2 x 96 wells

For the quantitative determination of intracellular FTO in human cell lysates.

SENSITIVITY: 50pg/ml (range 0.156 to 10ng/ml).

FTO (mouse) (IntraCellular) ELISA Kit

AG-45A-0028EK-KI01

AG-45A-0028TP-KI01 Twin Plex

1 x 96 wells

2 x 96 wells

For the quantitative determination of intracellular FTO in mouse cell lysates.

SENSITIVITY: 20pg/ml (range 0.156 to 10ng/ml).

thymine from other nucleotides [12]. A recent study has shown that FTO is a transcriptional coactivator for the C/EBP family of transcriptional regulators from unmethylated as well as methylated promoters and exhibits nuclease activity. Thus, FTO may play a role in the epigenetic regulation of fat tissue development and maintenance [13].

Based on twin studies, it was known for years, that the development of obesity in response to a particular environment underlies some genetic factors [14]. Some specific *FTO* gene variations were shown to correlate directly with obesity and even more, with type-II diabetes (T2D). The first intron of the *FTO* gene contains several SNPs (single nucleotide polymorphisms). 10 different SNPs correlating with an increased obesity risk have been identified within this intron [7]. The SNP rs9939609 A-allele for example increases the risk of obesity and T2D. Gathered data show that the effects on obesity are allelic dose dependent [7, 15]. Within the *FTO* gene, rs9930506 showed the strongest association with BMI (Body Mass Index), hip circumference, and weight [16]. These findings were reproduced for many Caucasian populations. Initial studies in Asians and lately also with an African population showed no association between *FTO* gene variants and the BMI or obesity [17-20]. However, other studies with Chinese, Koreans, Malay, Japanese, Europeans, Americans, and Hispanic Americans supported the association between *FTO* gene variants and obesity in such populations [16,19, 21-25]. Even though there is an association between *FTO* gene variants and the

susceptibility to obesity, this can be overcome in part by physical activity [26, 27].

Ubiquitous overexpression of *FTO* in mice results in increased food intake and leads to a dose-dependent increase in obesity [28-30].

Inactivation of the *Fto* gene protects mice from obesity. The generated *Fto*-null mice lead to postnatal growth retardation and a significant reduction in adipose tissue and lean body mass [31]. However, the induction of hypothalamus development seems to be normal. The leanness of *Fto*-deficient mice results from an increased energy expenditure in the presence of reduced spontaneous locomotor activity with a relative hyperphagia. Interestingly, human carriers of the *FTO* gene risk allele seem to develop obesity as a consequence of hyperphagia, without altered energy expenditure as observed in mice [31]. The results are so far the first direct evidence of the energy homeostasis function of FTO. In contrast to *Fto*-deficient mice that, apart from the leanness phenotype, only show postnatal growth retardation, a loss-of-function mutation in the human *FTO* gene has been shown to cause a severe polymalformation syndrome. This indicates that FTO, apart from correlating with obesity, also is essential for normal development in human and might have different roles in different tissues [32, 33].

Literature References

[1] Cloning of Fatso (Fto), a novel gene deleted by the Fused toes (Ft) mouse mutation: T. Peters, et al.; Mamm. Genome **10**, 983 (1999) ▪ [2] The mouse Fused toes (Ft) mutation is the result of a 1.6-Mb deletion including the entire Iroquois B gene cluster: T. Peters et al.; Mamm. Genome **13**, 186 (2002) ▪ [3] Regulation of Fto/Ftm gene expression in mice and humans: G. Stratigopoulos, et al.; Am. J. Physiol. Regul. Integr. Comp. Physiol. **294**, 1185 (2008) ▪ [4] The obesity-associated FTO gene encodes a 2-Oxoglutarate-dependent nucleic acid demethylase: T. Gerken, et al.; Science **318**, 1469 (2007) ▪ [5] Regulation and function of FTO mRNA expression in human skeletal muscle and subcutaneous adipose tissue: L.G. Grunnet, et al.; Diabetes **58**, 2402 (2009) ▪ [6] The obesity gene, FTO, is of ancient origin, up-regulated during food deprivation and expressed in neurons of feeding-related nuclei of the brain: R. Fredriksson, et al.; Endocrinology **149**, 2062 (2008) ▪ [7] A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity: T.M. Frayling, et al.; Science **316**, 889 (2007) ▪ [8] Variation in FTO contributes to childhood obesity and severe adult obesity: C. Dina, et al.; Nat. Genet. **39**, 724 (2007) ▪ [9] The FTO gene, implicated in human obesity, is found only in vertebrates and marine algae: S. Robbens, et al.; J. Mol. Evol. **66**, 80 (2008) ▪ [10] The FTO (fat mass and obesity associated) gene codes for a novel member of the non-heme dioxygenase superfamily: L. Sanchez-Pulido, et al.; BMC Biochem. **8**, 23 (2007) ▪ [11] Oxidative demethylation of 3-methylthymine and 3-methyluracil in single-stranded DNA and RNA by mouse and human FTO: G. Jia, et al.; FEBS Lett. **582**, 3313 (2008) ▪ [12] Crystal structure of the FTO protein reveals basis for its substrate specificity: Z. Han, et al.; Nature **464**, 1205 (2010) ▪ [13] The obesity-associated Fto gene is a transcriptional coactivator: Q. Wu, et al.; BBRC **401**, 390 (2010) ▪ [14] Genetic and environmental factors in relative body weight and human adiposity: H.H.M. Maes, et al.; Behav. Genet. **27**, 325 (1997) ▪ [15] Effect of an FTO polymorphism on fat mass, obesity, and type 2 diabetes mellitus in the French MONICA Study: V. Legry, et al.; Metabolism **58**, 971 (2009) ▪ [16] Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits: A. Scuteri, et al.; PLoS Genet. **3**, 1200 (2007) ▪ [17] Variants in

the fat mass- and obesity-associated (FTO) gene are not associated with obesity in a Chinese Han population: H. Li, et al.; Diabetes **57**, 264 (2008) ▪ [18] Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population: M. Horikoshi, et al.; Diabetologia **50**, 2461 (2007) ▪ [19] Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample: S.A. Al-Attar, et al.; Cardiovasc. Diabetol. **7**, 5 (2008) ▪ [20] FTO polymorphism in oceanic populations: J. Ohashi, et al.; J. Hum. Genet. **52**, 1031 (2007) ▪ [21] Replication of genetic effects of FTO polymorphisms on BMI in a Korean population: S.W. Cha, et al.; Obesity **16**, 2187 (2008) ▪ [22] Common variation in the fat mass and obesity-associated (FTO) gene confers risk of obesity and modulates BMI in the Chinese population: Y.C. Chang, et al.; Diabetes **57**, 2245 (2008) ▪ [23] FTO variants are associated with obesity in the Chinese and Malay populations in Singapore: J.T. Tan, et al.; Diabetes **57**, 2851 (2008) ▪ [24] Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population: S. Omori, et al.; Diabetes **57**, 791 (2008) ▪ [25] Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians: M.C. Ng, et al.; Diabetes **57**, 2226 (2008) ▪ [26] The genetics of obesity: FTO leads the way: K.A. Fawcett & I. Barroso; Trends Genet. **26**, 266 (2010) ▪ [27] Physical activity attenuates the body mass index-increasing influence of genetic variation in the FTO gene: K.S. Vimalaswaran, et al.; Am. J. Clin. Nutr. **90**, 425 (2009) ▪ [28] Overexpression of Fto leads to increased food intake and results in obesity: C. Church, et al.; Nat. Genet. **42**, 1086 (2010) ▪ [29] FTO gains function: G. Stratigopoulos & R.L. Leibel; Nat. Genet. **42**, 1083 (2010) ▪ [30] Prevalence of loss-of-function FTO mutations in lean and obese individuals: D. Meyre, et al.; Diabetes **59**, 311 (2010) ▪ [31] Inactivation of the Fto gene protects from obesity: J. Fischer, et al.; Nature **458**, 894 (2009) ▪ [32] Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations: S. Boissel, et al.; Am. J. Hum. Genet. **85**, 106 (2009) ▪ [33] Where to go with FTO?: R. Larder, et al.; Trends Endocrinol. Metab. **Epub ahead of print** (2010)

NEW**mAb AG103 – A Powerful Tool for FTO Studies****new  anti-FTO (human), mAb (AG103)**AG-20A-0092-C050 50 µg
AG-20A-0092-C100 100 µg

CLONE: AG103. ISOTYPE: Mouse IgG2ak. IMMUNOGEN: Recombinant human FTO. SPECIFICITY: Recognizes human FTO. APPLICATION: IHC (PS), IP, WB.




FIGURE: Immunohistochemical staining of FTO with anti-FTO (human), mAb (AG103) (Prod. No. AG-20A-0092) in brain, hypothalamus and paraventricular nucleus (5~10 µg/ml).

This antibody has been tested in immunohistochemistry, analyzed by an anatomic pathologist and validated for use in IHC applications against formalin-fixed, paraffin-embedded human tissues. The image shows the localization of the antibody as the precipitated red signal, with a hematoxylin purple nuclear counterstain (40x).

FIGURE: Western blot using human cell lysates.

1. HEK293T (100µg)
2. HEK293E (100µg)
3. HepG2 (100µg)
4. Hep3B (50µg)
5. V1T1 (100µg)
6. THP1 (100µg)
7. Molt4 (100µg)
8. A549 (50µg)






FIGURE: Immunoprecipitation.

1. Molt4 1mg
2. Molt4 500µg
3. Molt4 250µg
4. Molt4 125µg
5. Molt4 62.5µg
6. Molt4 31.2µg
7. Molt4 15.6µg

**A. IP & silver staining**

1. IP ; IgG control + RIPA control
2. IP ; IgG control + Molt4 1mg
3. IP ; AG103 + RIPA control
4. IP ; AG103 + Molt4 1mg

B. Base peak chromatogram of in-gel digests**C. MS-MS spectrum****D. Protein sequence coverage (21%)**

```

1  MKRPTAEER EREAAGLRLL ELEDTULPY LTPKDEEYQ QVQLKYPKLI LREASSVSEE
61  LHKVEQEAFL TLHGHCGLFR DLVRIQKQL LTPVSEILIG NPGCTYKYNL TRLFTVPVPV
121  KGSNIHQTEA EIAAACETFL KLDYLIQIET IQALEELAAK EKANEDAVPL CMSADFFRVG
181  MGSYNGQDE VDIKSR AAYN VTLNFMDFPK MPYLKEEY FGHGKHAVSW HHDENLVDRS
241  AVAVYSYSC EPEESEDDE HLEGR DPDIW HVGKKISWDI ETPGLAIFLH QGDCYFMLDD
301  LNATHQHCVL AGSQPRFSST HRVAECSTGT LDYILQRCQL ALQNVCDVD NDDVSLKSE
361  PAYLKQGEI HNEVEFELR QFMFQGNRYR KCTDWQCPL AQLEALUKKH EGVTVAVLHE
421  VKREGLPVEQ RNEILTALIA SLTARQNLRR EWHARCQRI ARTLPADQKP ECRPYWEKDD
481  ASHPLPDLT DIVSELRGQL LEAKP
  
```

Peptide 1. DPDIWHVGFK

Peptide 2. AAYNVTLNFMDFPK

FIGURE: Mass analysis (LC/MS-MS) of native FTO.

Products

Antibodies

anti-FTO (human), pAb

AG-25A-0084-C100 100 µg
From rabbit. **IMMUNOGEN:** Recombinant human FTO. **SPECIFICITY:** Recognizes human FTO. **APPLICATION:** WB.

anti-FTO (mouse), pAb

AG-25A-0089-C100 100 µg
From rabbit. **IMMUNOGEN:** Recombinant mouse FTO. **SPECIFICITY:** Recognizes mouse FTO. Weakly cross-reacts with human FTO. **APPLICATION:** WB.

anti-FTO (human), mAb (FT86-4)

AG-20A-0064-C050 50 µg
AG-20A-0064-C100 100 µg
CLONE: FT86-4. **ISOTYPE:** Mouse IgG1κ. **IMMUNOGEN:** Recombinant human FTO. **SPECIFICITY:** Recognizes human FTO. **APPLICATION:** IP, WB.




FIGURE: Immunoprecipitation of recombinant human FTO protein by anti-FTO (human), mAb (FT86-4). Recombinant human FTO protein at different concentrations was precipitated by anti-hFTO mAb (FT86-4). The precipitated protein was separated by SDS-PAGE, electroblotted, and visualized by Western blot with rabbit anti-mouse FTO pAb (AG-25A-0089).

1. rhFTO-His control 100ng (AG-40A-0112)
2. rhFTO-His 5µg
3. rhFTO-His 2.5µg
4. rhFTO-His 1.25µg
5. rhFTO-His 0.625µg
6. rhFTO-His 0.312µg
7. rhFTO-His 0.156µg
8. rhFTO-His 0.078µg

new anti-FTO (mouse), mAb (FT62-6)

AG-20A-0083-C050 50 µg
AG-20A-0083-C100 100 µg
CLONE: FT62-6. **ISOTYPE:** Mouse IgG1κ. **IMMUNOGEN:** Recombinant human FTO. **SPECIFICITY:** Recognizes mouse FTO. Weakly cross-reacts with human FTO. Does not cross-react with rat FTO. **APPLICATION:** IHC (PS), IP, WB.




FIGURE: Immunohistochemical staining of FTO with anti-FTO (mouse) mAb (FT62-6) in mouse tissue (1:500 dilution, 200X).

- A. Immunoperoxidase staining of formalin-fixed, paraffin-embedded mouse brain.
A-1. Isotype control, mouse brain.
B. Immunoperoxidase staining of formalin-fixed, paraffin-embedded mouse uterus.
B-1. Isotype control, mouse uterus.

Proteins

FTO (human) (rec.) (His)

AG-40A-0112-C010 10 µg
AG-40A-0112-C050 50 µg
Expressed in *E. coli*. The mature peptide of human FTO (aa 2-502) is fused at the N-terminus to a His-tag. **PURITY:** ≥90% (SDS-PAGE). **ENDOTOXIN CONTENT:** <1EU/µg protein (LAL-test).

FTO (mouse) (rec.) (His)

AG-40A-0127-C010 10 µg
AG-40A-0127-C050 50 µg
Expressed in *E. coli*. The mature peptide of mouse FTO (aa 2-502) is fused at the N-terminus to a His-tag. **PURITY:** ≥90% (SDS-PAGE). **ENDOTOXIN CONTENT:** <1EU/µg protein (LAL-test).

new FTO (rat) (rec.) (His)

AG-40A-0146-C010 10 µg
AG-40A-0146-C050 50 µg
Expressed in *E. coli*. The mature peptide of rat FTO (aa 2-502) is fused at the N-terminus to a His-tag. **PURITY:** ≥90% (SDS-PAGE). **ENDOTOXIN CONTENT:** <1EU/µg protein (LAL-test).

new anti-FTO (mouse), mAb (FT342-1)

AG-20A-0088-C050 50 µg
AG-20A-0088-C100 100 µg
CLONE: FT342-1. **ISOTYPE:** Rat IgG2ακ. **IMMUNOGEN:** Recombinant mouse FTO. **SPECIFICITY:** Recognizes mouse FTO. Cross-reacts with rat FTO. Does not cross-react with human FTO. **APPLICATION:** WB.

Purified (PF) = Purified (Preservative free); FACS = Flow Cytometry; ICC = Immunocytochemistry; IP = Immunoprecipitation; IHC = Immunohistochemistry (FS = Frozen Sections, PS = Paraffin Sections); WB = Western blot; BP = Blocking Peptide

AdipoGen™
Connecting Immunology to Metabolism™
www.adipogen.com

EUROPE/REST OF WORLD
Adipogen International
TEL +41-61-926-60-40
FAX +41-61-926-60-49
info@adipogen.com

NORTH & SOUTH AMERICA
Adipogen Corp.
TEL +1-858-457-8383
FAX +1-858-457-8484
info@adipogen.com

SOUTH KOREA/ASIA
Adipogen, Inc.
TEL +82-32-858-1470
FAX +82-32-831-1470
info-kr@adipogen.com

For local distributors please visit our website.